A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Shih-Yao Lin, MD, PhD
AbGenomics B.V Taiwan Branch
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Uc San Diego
La Jolla, California, United States
- Stanford University
Palo Alto, California, United States
- Sarasota Arthritis Research Center
Sarasota, Florida, United States
- Northwestern University
Chicago, Illinois, United States
- Justus J. Fiechtner, Md, Pc
Lansing, Michigan, United States
- Metroplex Clinical Research Center, Llc
Dallas, Texas, United States
- Seattle Rheumatology Associates/swedish Clinical Research
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jan 2015
- Primary completion
- 31 Oct 2015
- Completion
- 31 Jan 2016
- Last update posted
- 24 Jan 2017
- Registered enrollment
- 20
- Registry id
- NCT02267642
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.